OrganiGram Holdings Inc.
TSX:OGI.TODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $135.37M
- Beta
- 1.84
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$0.19
Volume 0.54M
Average 0.19M
OGI.TO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
OrganiGram Holdings Inc.TSX: OGI.TO
Capital Expenditures · Q2 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q2 FY2026 capital expenditures of CA$223K (cash outflow) fell 96.6% year over year, behind the +1.5% change in trailing-twelve-month capital expenditures. Sequentially, it fell 89.4% from the prior quarter.
Context
- Capital expenditures amounted to 6.6% of revenue in FY2025, up 3.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -96.6% toward the trailing-twelve-month pace of +1.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
CAD · from the cash flow
- Latest · FY2025
- (17.05M) CAD
- Year-over-year change
- -219.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (17.05M) | -219.4% |
| FY2024 | 2024-09-30 | (5.34M) | +80.2% |
| FY2023 | 2023-09-30 | (26.9M) | +44.9% |
| FY2022 | 2022-08-31 | (48.78M) | -295.6% |
| FY2021 | 2021-08-31 | (12.33M) | — |
Capital Expenditures vs competitors
How OGI.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.5% is the 6th highest of 9, against a peer median of +24.4%.
- Capital expenditures amounts to 4.1% of revenue for OGI.TO, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$22.55M CAD | +19.5% | +22.9% | 7.1% | |
| LTM Mar 2026 | CA$11.19M CAD | +1.5% | — | 4.1% | |
| LTM Mar 2026 | $6.87M USD | -37.4% | -45.7% | 2.6% | |
| LTM Mar 2026 | CA$6.44M CAD | -42.9% | -17.4% | 2.1% | |
| LTM Mar 2026 | $5.72M USD | -6.0% | -9.6% | 1.9% | |
| LTM Mar 2026 | CA$3.26M CAD | +29.2% | -35.1% | 2.1% | |
| LTM Mar 2026 | $1.78M USD | +5138.8% | -72.6% | 3.2% | |
| LTM Mar 2026 | $727.56K USD | +188.2% | +24.8% | — | |
| LTM Mar 2026 | $107.42K USD | +168.5% | -29.4% | 0.2% | |
| LTM Mar 2026 | $3.64 USD | — | — | 0.0% | |
| Peer median (excluding OGI.TO) | — | +24.4% | -23.4% | 2.1% | |
Competitors are the stored peer set for OGI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Aug 2021 | FY2022 Aug 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (130.7M) | (14.28M) | (229.48M) | (45.44M) | (24.76M) |
| Depreciation & Amortization | 31.03M | 24.91M | 24.17M | 12.08M | 17.98M |
| Deferred Income Tax | 42.21M | (88K) | (3.62M) | 0 | (13.77M) |
| Stock-Based Compensation | 3.9M | 5.13M | 5.29M | 7.18M | 4.22M |
| Change in Working Capital | 24.2M | (22.88M) | 12.51M | 14.96M | (2.12M) |
| Accounts Receivables | (6.01M) | (24.02M) | 12.51M | (12.06M) | (15.29M) |
| Inventory | 28.68M | (12.22M) | 0 | 0 | 0 |
| Accounts Payables | 2.06M | 12.15M | 0 | 0 | 0 |
| Other Working Capital | (542K) | 1.21M | (5.52M) | 27.02M | 13.16M |
| Other Non-Cash Items | 776K | (29M) | 155.33M | 15.09M | 12.47M |
| Operating Cash Flow | (28.59M) | (36.21M) | (35.8M) | 3.87M | (7.59M) |
| Capital Expenditures | (12.33M) | (48.78M) | (26.9M) | (5.34M) | (17.05M) |
| Acquisitions (Net) | (2.54M) | (11.06M) | 1.03M | 257K | (65.62M) |
| Purchases of Investments | (120.02M) | (15M) | (10M) | (29.24M) | (1.01M) |
| Sales of Investments | 50.85M | 114.59M | 49.4M | 3.52M | 2.5M |
| Other Investing Activities | (31.08M) | 4.29M | (8.65M) | (7.97M) | (1.52M) |
| Investing Cash Flow | (115.11M) | 44.03M | 1.36M | (38.77M) | (82.67M) |
| Debt Repayment | (116.4M) | (1.01M) | (87K) | (786K) | (60K) |
| Common Stock Issued | 284.88M | 6.34M | 20K | 108.56M | 41.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.99M | 6.34M | (750K) | 6K | (1.79M) |
| Financing Cash Flow | 174.46M | 5.33M | (817K) | 107.78M | 39.33M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 313K |
| Net Change in Cash | 30.77M | 13.15M | (34.65M) | 72.88M | (49.01M) |
| Free Cash Flow | (40.92M) | (84.99M) | (62.7M) | (1.47M) | (24.64M) |
OrganiGram Holdings Inc.
TSX:OGI.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.